The application of Fe3O4 nanoparticles in cancer research: a new strategy to inhibit drug resistance.
Although much effort has been extended to the efficient cancer therapies, the drug resistance is still a major obstacle in cancer chemotherapeutic treatments. Almost 90% of the cancer therapy failure is caused by the relative problems. Recently, the application of drug coated polymer nanospheres and nanoparticles to inhibit the related drug resistance has attracted much attention. In this report, we have explored a novel strategy to inhibit the multidrug resistance of the targeted tumor cells by combining the unique properties of tetraheptylammonium capped Fe(3)O(4) magnetic nanoparticles with the drug accumulation of anticancer drug daunorubicin. Our results of confocal fluorescence and atomic force microscopy (AFM) as well as electrochemical studies demonstrate the remarkable synergistic effect of Fe(3)O(4) nanoparticles on drug uptake of daunorubicin in leukemia K562 cells. These observations indicate that the interaction between the magnetic nanoparticles Fe(3)O(4) and biologically active molecules on the membrane of leukemia cell lines may contribute to their beneficial effect on cellular uptake so that the synergistic enhanced effect of magnetic nanoparticles Fe(3)O(4) on drug uptake of drug resistance leukemia K562 cells could be observed upon application of the Fe(3)O(4) nanoparticles.
Wang
Xuemei
X
State Key Lab of Bioelectronics, Chien-Shiung Wu Laboratory, Southeast University, Nanjing 210096, People's Republic of China. xuewang@seu.edu.cn
Zhang
Renyun
R
Wu
Chunhui
C
Dai
Yongyuan
Y
Song
Min
M
Gutmann
Sebastian
S
Gao
Feng
F
Lv
Gang
G
Li
Jingyuan
J
Li
Xiaomao
X
Guan
Zhiqun
Z
Fu
Degang
D
Chen
Baoan
B
D000903:Antibiotics, Antineoplastic / Q000494:pharmacology* / Q000627:therapeutic use; D020099:Coated Materials, Biocompatible; D003630:Daunorubicin / Q000494:pharmacology* / Q000627:therapeutic use; D016503:Drug Delivery Systems; D018432:Drug Resistance, Multiple / Q000187:drug effects; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D005290:Ferric Compounds; D006801:Humans; D020014:K562 Cells; D007938:Leukemia / Q000188:drug therapy* / Q000473:pathology; D008280:Magnetics; D053758:Nanoparticles; D000644:Quaternary Ammonium Compounds
D000903:Antibiotics, Antineoplastic; D020099:Coated Materials, Biocompatible; D005290:Ferric Compounds; D000644:Quaternary Ammonium Compounds; C000499:ferric oxide; C055292:tetrahexylammonium; D003630:Daunorubicin